from Flow Cytometry to Cytomics

Blood cancers are complex; the symptoms are often vague and general, leading to late diagnoses – and with well over 100 different types of hematological malignancies, it’s not always easy to zero in on a conclusive diagnosis. When leukemia (or a similar disease) is suspected, attempts at diagnosis are painful and invasive for the patient, and time-consuming and labor-intensive for physicians. In June 2017, the FDA authorized a new test (Beckman Coulter’s ClearLLab LS) that aims to provide a simpler, more consistent way of detecting cancer-specific cell surface markers in blood, bone marrow, or lymph node samples (1). Enjoy our FREE content!